clinical trials

Research into human diseases has led to the development of novel monoclonal antibody drugs. These monoclonal antibody therapies have been successful because of their specificity and selectivity. However, ongoing development and successfully launching a new mAb drug require robust and reliable methods to screen for drug targets, demonstrate drug safety and efficacy, and scale up manufacturing to meet the stringent regulatory guidelines required for approval.

The ability to characterize the target of cell-mediated immune response is crucial during vaccine development. In studying the characterization of SARS-CoV-2 infection pathogenesis in humans, a research team identified neutralizing antibodies that provided context for vaccine antigen design. Discover how the ZE5 Cell Analyzer was used to detect activation-induced markers, measure intracellular cytokines, and identify spike protein–specific antibodies in a rapid, high-throughput manner.